Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 28 studies | 36% ± 14% | |
microglial cell | 10 studies | 40% ± 16% | |
myeloid cell | 7 studies | 30% ± 10% | |
leukocyte | 4 studies | 26% ± 13% | |
mononuclear phagocyte | 3 studies | 33% ± 21% | |
conventional dendritic cell | 3 studies | 25% ± 11% | |
mast cell | 3 studies | 20% ± 5% |
Insufficient scRNA-seq data for expression of GPR34 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 97% | 546.93 | 446 / 459 | 87% | 14.83 | 968 / 1118 |
brain | 67% | 269.30 | 1757 / 2642 | 99% | 74.34 | 697 / 705 |
lung | 85% | 432.03 | 494 / 578 | 76% | 12.26 | 883 / 1155 |
adrenal gland | 98% | 659.90 | 252 / 258 | 62% | 6.75 | 142 / 230 |
prostate | 88% | 286.50 | 216 / 245 | 67% | 6.45 | 337 / 502 |
intestine | 93% | 395.28 | 902 / 966 | 58% | 6.17 | 306 / 527 |
stomach | 77% | 173.84 | 277 / 359 | 67% | 10.12 | 193 / 286 |
bladder | 90% | 278.10 | 19 / 21 | 50% | 6.41 | 251 / 504 |
esophagus | 71% | 199.14 | 1026 / 1445 | 68% | 6.29 | 124 / 183 |
kidney | 51% | 157.87 | 45 / 89 | 82% | 21.69 | 735 / 901 |
ovary | 54% | 130.13 | 97 / 180 | 75% | 10.78 | 321 / 430 |
pancreas | 54% | 101.73 | 176 / 328 | 72% | 10.99 | 129 / 178 |
thymus | 57% | 142.08 | 370 / 653 | 67% | 7.28 | 404 / 605 |
uterus | 72% | 161.32 | 122 / 170 | 47% | 4.49 | 218 / 459 |
adipose | 99% | 853.10 | 1187 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 97% | 529.64 | 1293 / 1335 | 0% | 0 | 0 / 0 |
spleen | 93% | 1131.77 | 225 / 241 | 0% | 0 | 0 / 0 |
skin | 26% | 40.02 | 476 / 1809 | 57% | 7.23 | 267 / 472 |
tonsil | 0% | 0 | 0 / 0 | 71% | 6.52 | 32 / 45 |
lymph node | 0% | 0 | 0 / 0 | 59% | 9.29 | 17 / 29 |
liver | 22% | 41.06 | 50 / 226 | 35% | 3.17 | 144 / 406 |
heart | 52% | 111.70 | 450 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 43% | 131.52 | 403 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 21% | 1.60 | 17 / 80 |
muscle | 13% | 17.48 | 104 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0035589 | Biological process | G protein-coupled purinergic nucleotide receptor signaling pathway |
GO_0005886 | Cellular component | plasma membrane |
GO_0004930 | Molecular function | G protein-coupled receptor activity |
GO_0045028 | Molecular function | G protein-coupled purinergic nucleotide receptor activity |
Gene name | GPR34 |
Protein name | G-protein-coupled receptor 34 splice variant Probable G-protein coupled receptor 34 |
Synonyms | hCG_1818087 |
Description | FUNCTION: G-protein-coupled receptor of lysophosphatidylserine (LysoPS) that plays different roles in immune response . Acts a damage-sensing receptor that triggers tissue repair upon recognition of dying neutrophils (By similarity). Mechanistically, apoptotic neutrophils release lysophosphatydilserine that are recognized by type 3 innate lymphoid cells (ILC3s) via GPR34, which activates downstream PI3K-AKT and RAS-ERK signaling pathways leading to STAT3 activation and IL-22 production (By similarity). Plays an important role in microglial function, controlling morphology and phagocytosis (By similarity). . |
Accessions | Q3SAH2 ENST00000378138.5 ENST00000378142.9 Q9UPC5 ENST00000649219.1 Q3SAH0 Q5VT14 |